Lisata Therapeutics Shares Tumble After Pancreatic Cancer Treatment Results

Dow Jones2025-01-23

By Katherine Hamilton

Lisata Therapeutics shares dropped after a pancreatic cancer treatment trial didn't show significant improvement in patient survival.

The stock fell 32% to $2.64 on Wednesday, losing all its gains over the past month.

The Phase 2 trial studied the efficacy of certepetide as a treatment for pancreatic cancer. There was no significant improvement in median progression-free survival, which was five and a half months for both treated and placebo groups, the company said.

Preliminary results did show treated patients survived about 12.7 months compared with 9.7 months in the placebo group.

Lisata plans to advance certepetide development to Phase 3 in 2026, it said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

January 22, 2025 13:58 ET (18:58 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2505772481?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-23 02:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505772481","market":"sg","top_or_hot":-1,"title":"Lisata Therapeutics Shares Tumble After Pancreatic Cancer Treatment Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  Lisata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares dropped after a pancreatic cancer treatment trial didn't show significant improvement in patient survival. \n</p>\n<p>\n  The stock fell 32% to $2.64 on Wednesday, losing all its gains over the past month. \n</p>\n<p>\n  The Phase 2 trial studied the efficacy of certepetide as a treatment for pancreatic cancer. There was no significant improvement in median progression-free survival, which was five and a half months for both treated and placebo groups, the company said. \n</p>\n<p>\n  Preliminary results did show treated patients survived about 12.7 months compared with 9.7 months in the placebo group. \n</p>\n<p>\n  Lisata plans to advance certepetide development to Phase 3 in 2026, it said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 22, 2025 13:58 ET (18:58 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lisata Therapeutics Shares Tumble After Pancreatic Cancer Treatment Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLisata Therapeutics Shares Tumble After Pancreatic Cancer Treatment Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-23 02:58</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  Lisata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares dropped after a pancreatic cancer treatment trial didn't show significant improvement in patient survival. \n</p>\n<p>\n  The stock fell 32% to $2.64 on Wednesday, losing all its gains over the past month. \n</p>\n<p>\n  The Phase 2 trial studied the efficacy of certepetide as a treatment for pancreatic cancer. There was no significant improvement in median progression-free survival, which was five and a half months for both treated and placebo groups, the company said. \n</p>\n<p>\n  Preliminary results did show treated patients survived about 12.7 months compared with 9.7 months in the placebo group. \n</p>\n<p>\n  Lisata plans to advance certepetide development to Phase 3 in 2026, it said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 22, 2025 13:58 ET (18:58 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2505772481","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505772481","pubTimestamp":1737572280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Lisata Therapeutics shares dropped after a pancreatic cancer treatment trial didn't show significant improvement in patient survival.The stock fell 32% to $2.64 on Wednesday, losing all its gains over the past month.The Phase 2 trial studied the efficacy of certepetide as a treatment for pancreatic cancer. There was no significant improvement in median progression-free survival, which was five and a half months for both treated and placebo groups, the company said.Preliminary results did show treated patients survived about 12.7 months compared with 9.7 months in the placebo group.Lisata plans to advance certepetide development to Phase 3 in 2026, it said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","LSTA":"LISATA THERAPEUTICS INC","BK4139":"生物科技"},"translate_title":"胰腺癌治疗结果公布后，Lisata Therapeutics股价暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LSTA":0.9,"LENZ":1},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Lisata Therapeutics shares dropped after a pancreatic cancer treatment trial didn't show significant improvement in patient survival. \n\n\n  The stock fell 32% to $2.64 on Wednesday, losing all its gains over the past month. \n\n\n  The Phase 2 trial studied the efficacy of certepetide as a treatment for pancreatic cancer. There was no significant improvement in median progression-free survival, which was five and a half months for both treated and placebo groups, the company said. \n\n\n  Preliminary results did show treated patients survived about 12.7 months compared with 9.7 months in the placebo group. \n\n\n  Lisata plans to advance certepetide development to Phase 3 in 2026, it said. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 22, 2025 13:58 ET (18:58 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2505772481","isCrawlerRequest":true}